Malmö, Sweden

Per Anders Tunek

This inventor holds 3 USPTO granted patents. Top assignees: Aktiebolaget Draco, Astra Aktiebolag. Active years: 1994-1999.


% Patents Active = 100.0

Average Co-Inventor Count = 2.5

ph-index = 2

Forward Citations = 13(Granted Patents)


Location History:

  • Malmo both of, SE (1994)
  • Malmo, SE (1994 - 1999)

Company Filing History:


Years Active: 1994-1999

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Per Anders Tunek: Innovator in Pharmaceutical Chemistry

Introduction

Per Anders Tunek is a notable inventor based in Malmö, Sweden. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative patents. With a total of 3 patents, Tunek has focused on developing compounds with therapeutic applications.

Latest Patents

Among his latest patents, Tunek has developed 3,3'-dithiobis(propionic acids) and esters thereof, which possess immunomodulating effects. These compounds are accompanied by processes for their preparation, pharmaceutical compositions containing them, and methods of their pharmacological use. Additionally, he has worked on derivatives of cysteine, which are useful for treating various lung diseases.

Career Highlights

Throughout his career, Tunek has been associated with prominent companies such as Aktiebolaget Draco and Astra Aktiebolag. His work in these organizations has allowed him to advance his research and contribute to the development of innovative pharmaceutical solutions.

Collaborations

Tunek has collaborated with notable individuals in his field, including Anders R Hallberg and Carl-Magnus Alexander Andersson. These partnerships have further enriched his research and development efforts.

Conclusion

Per Anders Tunek's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as an influential inventor. His work continues to impact the field positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…